Frontiers in Oncology | Pharmacology of Anti-Cancer Drugs

Original Research

Accepted on 20 Nov 2025

Human fibrosarcoma cells selected for ultra-high doxorubicin resistance, acquire trabectedin cross-resistance, remain sensitive to recombinant methioninase, and have increased c-MYC expression

in Pharmacology of Anti-Cancer Drugs

Sei Morinaga
Qinghong Han
Kohei Mizuta
Byung Mo Kang
Michael Bouvet
Norio Yamamoto
Katsuhiro Hayashi
Hiroaki Kimura
Shinji Miwa
Kentaro Igarashi

Frontiers in Oncology

Correction

Published on 17 Nov 2025

Correction: Lathyrol inhibits the proliferation of Renca cells by altering expression of TGF-β/Smad pathway components and subsequently affecting the cell cycle

in Pharmacology of Anti-Cancer Drugs

Shengyou Song
Yalin Song

Frontiers in Oncology

doi 10.3389/fonc.2025.1725790

152 views

Original Research

Accepted on 14 Nov 2025

The Value of 18F-FDG PET/CT Imaging in Predicting the Efficacy of PD-1/PD-L1 Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer

in Pharmacology of Anti-Cancer Drugs

Jian Wang
Huiwen Luo
Linlin Li
Xuefeng Hou
Xiaofeng Li
Wengui Xu
Wen Zhou
Dong Dai

Frontiers in Oncology

606 views

Original Research

Accepted on 14 Nov 2025

Antitumor efficasy of 5-aminolevulinic acid (5-ALA)-based radiodynamic therapy under single-dose X-ray irradiation in colon cancer

in Pharmacology of Anti-Cancer Drugs

Junko Takahashi
Shinsuke Nagasawa
Xiupeng Wang

Frontiers in Oncology

Review

Published on 06 Nov 2025

Consensus on managing delayed methotrexate elimination in high-dose therapy: insights from the Middle East

in Pharmacology of Anti-Cancer Drugs

Mubarak Al Manasour
Ahmad Absi
Ahmad Alhuraiji
Muhammad Faisal Khanani
Kayane Mheidly
Mohamed Elsaid
Walid Ballourah
Murtadha Al-Khabori
Naser Al Zain
Nisreen Khalifa

Frontiers in Oncology

doi 10.3389/fonc.2025.1660937

713 views

Brief Research Report

Published on 05 Nov 2025

Serial TIL infusions and PD-1 blockade drive long-term clonal persistence in prostate cancer

in Pharmacology of Anti-Cancer Drugs

Lucas C. M. Arruda
Julia Karbach
Dragan Kiselicki
Kathrin Brand
Claudia Wahle
Evgueni Sinelnikov
Dirk Gustavus
Hans Hoffmeister
Akin Atmaca
Elke Jäger

Frontiers in Oncology

doi 10.3389/fonc.2025.1693912

1,061 views

Original Research

Published on 05 Nov 2025

Artificial intelligence-based evaluation of prognostic benefits from immunotherapy plus targeted therapy with or without radiotherapy or TACE in advanced hepatocellular carcinoma

in Pharmacology of Anti-Cancer Drugs

Yuehong Deng
Shiqin Song
Huarong Zhao
Yuqian Yang
Simin Lu
Xueting Li

Frontiers in Oncology

doi 10.3389/fonc.2025.1694565

561 views

Original Research

Published on 03 Nov 2025

Mechanism of active component β-sitosterol from Myristica fragrans inducing apoptosis in bladder cancer cells via regulating the BCL-2/BAX/caspase-3 pathway

in Pharmacology of Anti-Cancer Drugs

Yongkang Zhu
Zhao Tang
Zhaoyue Lu
Dongyang Gao
Hao Pan
Haozhe Jiang
Zhen Zhang
Huiqing Zhang

Frontiers in Oncology

doi 10.3389/fonc.2025.1698721

529 views

Original Research

Published on 29 Oct 2025

Experimental study on the treatment of norepinephrine transporter-overexpressing pheochromocytomas and paragangliomas: a synthetic lethality strategy combining 131I-MIBG with PARP inhibitors

in Pharmacology of Anti-Cancer Drugs

Jieping Song
Lulu Zhang
Fan Qiu
Xiumin Shi
Rui Tian
Chuan Zhang
Xiaoyuan Li
Feng Wang

Frontiers in Oncology

doi 10.3389/fonc.2025.1681054

435 views

Review

Accepted on 27 Oct 2025

Overcoming resistance in advanced urothelial carcinoma: Mechanisms of escape from antibody-drug conjugates and FGFR3 inhibition

in Pharmacology of Anti-Cancer Drugs

Brandon Wummer
Michael Schwartz
Jordan Alana Ciuro
Shahid Sattar Ahmed
Shreyas Joshi
Vikram M Narayan
Bradley C Carthon
Mehmet Asim Bilen
Jacqueline Theresa Brown

Frontiers in Oncology

240 views

Review

Accepted on 22 Oct 2025

PARP Inhibitors as Radiosensitizers: A Comprehensive Review of Preclinical Evidence and Clinical Applications

in Pharmacology of Anti-Cancer Drugs

Shude Yang
Shuo Gao
Kaiyang Sun
Zhiqiang Dong
Xiaodong Luo

Frontiers in Oncology

382 views

Review

Accepted on 22 Oct 2025

Artificial Intelligence in Oncology Drug Development and Management: A Precision Medicine Perspective

in Pharmacology of Anti-Cancer Drugs

QingWei Yang
Caixia Fang
Pengfa Zhou
Xuerong Zhang
Yongsheng He

Frontiers in Oncology

620 views

Review

Published on 21 Oct 2025

Overcoming cancer drug resistance: insights into Apoptotic pathway modulation by plant-based nanoparticle and natural products

in Pharmacology of Anti-Cancer Drugs

Amit Kumar Singh
Prem Prakash Kushwaha
Ajaya Kumar Singh
Abhay K. Pandey

Frontiers in Oncology

doi 10.3389/fonc.2025.1677380

1,391 views

Systematic Review

Published on 15 Oct 2025

Evaluating the efficacy and safety of tebentafusp in the treatment of metastatic uveal melanoma: a 2025 update systematic review and meta-analysis

in Pharmacology of Anti-Cancer Drugs

Yanlin Wang
Wen Sun
Bing Wang

Frontiers in Oncology

doi 10.3389/fonc.2025.1667282

1,585 views

Review

Published on 13 Oct 2025

The role of cytostatic in oxidative stress reactions

in Pharmacology of Anti-Cancer Drugs

Renata Polaniak
Aleksander Kwiatkowski
Michał Górski
Elżbieta Grochowska-Niedworok
Małgorzata Latocha

Frontiers in Oncology

doi 10.3389/fonc.2025.1667522

1,017 views

Case Report

Published on 13 Oct 2025

A case report of malignant hypertension and multiorgan dysfunction during immunotherapy for gallbladder cancer

in Pharmacology of Anti-Cancer Drugs

Caroline Anthon
Hugo Pierret
Frederic Houssiau
Astrid De Cuyper
Cédric Van Marcke
Marc Van Den Eynde
Filomena Mazzeo
Frank Cornelis
Rachel Galot
Francois P. Duhoux

Frontiers in Oncology

doi 10.3389/fonc.2025.1658621

932 views